Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 8,372 shares, a decline of 43.1% from the August 15th total of 14,705 shares. Based on an average trading volume of 9,188,161 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the shares of the company are sold short.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for approximately 0.3% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 19th largest holding. Yorkville Advisors Global LP owned approximately 7.57% of Redhill Biopharma at the end of the most recent reporting period. 7.20% of the stock is owned by hedge funds and other institutional investors.
Redhill Biopharma Stock Down 4.8%
Shares of NASDAQ:RDHL opened at $0.61 on Tuesday. Redhill Biopharma has a fifty-two week low of $0.57 and a fifty-two week high of $2.79. The company has a market cap of $3.73 million, a PE ratio of 0.00 and a beta of 4.96. The company’s 50-day moving average price is $0.67 and its 200 day moving average price is $0.82.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Redhill Biopharma
About Redhill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.
RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.
Featured Stories
- Five stocks we like better than Redhill Biopharma
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
